Antibiotic Development: As FDA’s QIDP List Grows Longer, Will Firms GAIN Less?
So far, FDA has issued 24 Qualified Infectious Disease Product designations for 16 chemical entities, including to several products for the same infection; Cubist official says products also will have to show value.
You may also be interested in...
Developing new drugs is only one of the four actions to prevent antibiotic resistance CDC calls for in a report that encourages “stewardship” of available therapies.
Antibiotic-focused biotech can earn $58 million over five years under the government contract, which provides for testing of the novel macrolide in pediatric indications and for protection against bioterror-threat pathogens.
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?